Hyperthermia enhances the sensitivity of pancreatic cancer SW1990 cells to gemcitabine through ROS/JNK signaling

Jin,Hangbin; Zhao,Yanyan; Yang,Jianfeng; Zhang,Xiaofeng; Ma,Shenglin

doi:10.3892/ol.2018.9455

Hyperthermia enhances the sensitivity of pancreatic cancer SW1990 cells to gemcitabine through ROS/JNK signaling

Authors:
- Hangbin Jin
- Yanyan Zhao
- Jianfeng Yang
- Xiaofeng Zhang
- Shenglin Ma
View Affiliations

Affiliations: Department of Gastroenterology, Hangzhou First People's Hospital, Nanjing Medical University, Hangzhou, Zhejiang 310006, P.R. China, Department of Oncology, Hangzhou First People's Hospital, Nanjing Medical University, Hangzhou, Zhejiang 310006, P.R. China
Published online on: September 18, 2018 https://doi.org/10.3892/ol.2018.9455
Pages: 6742-6748

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Pancreatic cancer (PC) is a highly aggressive type of cancer. Gemcitabine (GEM) is a standard chemotherapeutic treatment of advanced PC; however, it requires improvement, and more effective therapeutic methods must be further explored. In the present study, hyperthermia combined with GEM was used on the PC cell line SW1990. The results revealed that mild hyperthermia (at 42˚C) effectively increased the inhibitory effect of GEM on cell viability, as determined using an MTT assay, and increased the effect of GEM‑induced apoptosis, as determined using an Annexin V‑fluorescein isothiocyanate/propidium iodide assay, in PC SW1990 cells. Additionally, it resulted in increased S‑phase arrest, downregulated the expression of the anti‑apoptosis protein B‑cell lymphoma 2 and upregulated the expression of the pro‑apoptosis protein Bcl‑2‑associated X protein, cleaved caspase‑3 and cleaved caspase‑9, as determined using a reverse transcription‑quantitative polymerase chain reaction and western blot analysis. Furthermore, it was revealed that hyperthermia resulted in the rapid generation of reactive oxygen species (ROS) and substantial activation of c‑Jun‑N‑terminal kinase (JNK). The introduction of ROS and JNK inhibitors suppressed hyperthermia‑induced apoptosis in GEM‑treated cells, suggesting that hyperthermia increased GEM cytotoxicity in PC SW1990 cells by inducing apoptosis via the ROS/JNK signaling pathway.

View Figures

View References

1	Worni M, Guller U, White RR, Castleberry AW, Pietrobon R, Cerny T, Gloor B and Koeberle D: Modest improvement in overall survival for patients with metastatic pancreatic cancer: A trend analysis using the surveillance, epidemiology, and end results registry from 1988 to 2008. Pancreas. 42:1157–1163. 2013. View Article : Google Scholar : PubMed/NCBI
2	Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
3	Ottaiano A, Capozzi M, De Divitiis C, De Stefano A, Botti G, Avallone A and Tafuto S: Gemcitabine mono-therapy versus gemcitabine plus targeted therapy in advanced pancreatic cancer: A meta-analysis of randomized phase III trials. Acta Oncol. 56:377–383. 2017. View Article : Google Scholar : PubMed/NCBI
4	Bednar F and Simeone DM: Recent advances in pancreatic surgery. Curr Opin Gastroenterol. 30:518–523. 2014. View Article : Google Scholar : PubMed/NCBI
5	Ghaneh P, Smith R, Tudor-Smith C, Raraty M and Neoptolemos JP: Neoadjuvant and adjuvant strategies for pancreatic cancer. Eur J Surg Oncol. 34:297–305. 2008. View Article : Google Scholar : PubMed/NCBI
6	Viaud J, Brac C, Artru P, Le Pabic E, Leconte B, Bodère A, Pracht M, Le Sourd S, Edeline J and Lièvre A: Gemcitabine as second-line chemotherapy after Folfirinox failure in advanced pancreatic adenocarcinoma: A retrospective study. Dig Liver Dis. 49:692–696. 2017. View Article : Google Scholar : PubMed/NCBI
7	Massari F, Santoni M, Ciccarese C, Brunelli M, Conti A, Santini D, Montironi R, Cascinu S and Tortora G: Emerging concepts on drug resistance in bladder cancer: Implications for future strategies. Crit Rev Oncol Hematol. 96:81–90. 2015. View Article : Google Scholar : PubMed/NCBI
8	Immordino ML, Brusa P, Rocco F, Arpicco S, Ceruti M and Cattel L: Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing lipophilic gemcitabine prodrugs. J Control Release. 100:331–346. 2004. View Article : Google Scholar : PubMed/NCBI
9	Kim CE, Lim SK and Kim JS: In vivo antitumor effect of cromolyn in PEGylated liposomes for pancreatic cancer. J Control Release. 157:190–195. 2012. View Article : Google Scholar : PubMed/NCBI
10	Maeda H, Wu J, Sawa T, Matsumura Y and Hori K: Tumor vascular permeability and the EPR effect in macromolecular therapeutics: A review. J Control Release. 65:271–284. 2000. View Article : Google Scholar : PubMed/NCBI
11	Kirui DK, Celia C, Molinaro R, Bansal SS, Cosco D, Fresta M, Shen H and Ferrari M: Mild hyperthermia enhances transport of liposomal gemcitabine and improves in vivo therapeutic response. Adv Healthc Mater. 4:1092–1103. 2015. View Article : Google Scholar : PubMed/NCBI
12	Shamir ER and Ewald AJ: Adhesion in mammary development: Novel roles for E-cadherin in individual and collective cell migration. Curr Top Dev Biol. 112:353–382. 2015. View Article : Google Scholar : PubMed/NCBI
13	Nicoletti I, Migliorati G, Pagliacci MC, Grignani F and Riccardi C: A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods. 139:271–279. 1991. View Article : Google Scholar : PubMed/NCBI
14	Hobot J, Carlemalm E, Villiger W and Kellenberger E: Periplasmic Gel: New concept resulting from the reinvestigation of bacterial cell envelope ultrastructure by new methods. J Bacteriol. 160:143–152. 1984.PubMed/NCBI
15	Li E, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchisio PC and Altieri DC: Control of apoptosis and mitotic spindle checkpoint by survivin. Nature. 396:580–584. 1998. View Article : Google Scholar : PubMed/NCBI
16	Gaitanaki C, Mastri M, Aggeli IK and Beis I: Differential roles of p38-MAPK and JNKs in mediating early protection or apoptosis in the hyperthermic perfused amphibian heart. J Exp Biol. 211:2524–2532. 2008. View Article : Google Scholar : PubMed/NCBI
17	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
18	de Sousa Cavalcante L and Monteiro G: Gemcitabine: Metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer. Eur J Pharmacol. 741:8–16. 2014. View Article : Google Scholar : PubMed/NCBI
19	van der Zee J: Heating the patient: A promising approach? Ann Oncol. 13:1173–1184. 2002. View Article : Google Scholar : PubMed/NCBI
20	Falk MH and Issels RD: Hyperthermia in oncology. Int J Hyperthermia. 17:1–18. 2001. View Article : Google Scholar : PubMed/NCBI
21	San-Miguel ICB, Vallejo D, Álvarez M, Prieto J, González-Gallego J and Tuñón MJ: Melatonin modulates the autophagic response in acute liver failure induced by the rabbit hemorrhagic disease virus. J Pineal Res. 56:313–321. 2014. View Article : Google Scholar : PubMed/NCBI
22	Guo Y, Ziesch A, Hocke S, Kampmann E, Ochs S, De Toni EN, Göke B and Gallmeier E: Overexpression of heat shock protein 27 (HSP27) increases gemcitabine sensitivity inpancreatic cancer cells through S-phase arrest and apoptosis. J Cell Mol Med. 19:340–350. 2015. View Article : Google Scholar : PubMed/NCBI
23	Nakajima K, Yanagawa T, Watanabe H and Takagishi K: Hyperthermia reduces migration of osteosarcoma by suppression of autocrine motilityfactor. Oncol Rep. 28:1953–1958. 2012. View Article : Google Scholar : PubMed/NCBI
24	Jin S, Shen JN, Wang J, Huang G and Zhou JG: Oridonin induced apoptosis through Akt and MAPKs signaling pathways in human osteosarcoma cells. Cancer Biol Ther. 6:261–268. 2007. View Article : Google Scholar : PubMed/NCBI
25	Cheng Y, Qiu F, Ye YC, Tashiro S, Onodera S and Ikejima T: Oridonin induces G2/M arrest and apoptosis via activating ERK-p53 apoptotic pathway and inhibiting PTK-Ras-Raf-JNK survival pathway in murine fibrosarcoma L929 cells. Arch Biochem Biophys. 490:70–75. 2009. View Article : Google Scholar : PubMed/NCBI
26	Shi Y: Caspase activation: Revisiting the induced proximity model. Cell. 117:855–858. 2004. View Article : Google Scholar : PubMed/NCBI
27	Takeda H, Okada M, Suzuki S, Kuramoto K, Sakaki H, Watarai H, Sanomachi T, Seino S, Yoshioka T and Kitanaka C: Rho-associated protein kinase (ROCK) inhibitors inhibit survivin expression and sensitize pancreatic cancer stem cells to gemcitabine. Anticancer Res. 36:6311–6318. 2016. View Article : Google Scholar : PubMed/NCBI
28	Filomeni G, De Zio D and Cecconi F: Oxidative stress and autophagy: The clash between damage and metabolic needs. Cell Death Differ. 22:377–388. 2015. View Article : Google Scholar : PubMed/NCBI
29	Renschler MF: The emerging role of reactive oxygen species in cancer therapy. Eur J Cancer. 40:1934–1940. 2004. View Article : Google Scholar : PubMed/NCBI
30	Toler SM, Noe D and Sharma A: Selective enhancement of cellular oxidative stress by chloroquine: Implications for the treatment of glioblastoma multiforme. Neurosurg Focus. 21:E102006. View Article : Google Scholar : PubMed/NCBI
31	Scandalios JG: Oxidative stress: Molecular perception and transduction of signals triggering antioxidant gene defenses. Braz J Med Biol Res. 38:995–1014. 2005. View Article : Google Scholar : PubMed/NCBI
32	Son Y, Cheong YK, Kim NH, Chung HT, Kang DG and Pae HO: Mitogen-activated protein kinases and reactive oxygen species: How can ROS activate MAPK pathways? J Signal Transduct 2011. 7926392011.
33	Dhillon AS, Hagan S, Rath O and Kolch W: MAP kinase signalling pathways in cancer. Oncogene. 26:3279–3290. 2017. View Article : Google Scholar
34	Liu QR, Liu JM, Chen Y, Xie XQ, Xiong XX, Qiu XY, Pan F, Liu D, Yu SB and Chen XQ: Piperlongumine inhibits migration of glioblastoma cells via activation of ROS-dependent p38 and JNK signaling pathways. Oxid Med Cell Longev. 2014:6537322014. View Article : Google Scholar : PubMed/NCBI
35	Goldsmith EJ, Min X, He H and Zhou T: Structural studies of MAP kinase cascade components. Methods Mol Biol. 661:223–237. 2010. View Article : Google Scholar : PubMed/NCBI
36	Johnson GL and Lapadat R: Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science. 298:1911–1912. 2002. View Article : Google Scholar : PubMed/NCBI
37	Lencioni R, Chen XP, Dagher L and Venook AP: Treatment of intermediate/advanced hepatocellular carcinoma in the clinic: How can outcomes be improved? Oncologist. 15 Suppl 4:S42–S52. 2010. View Article : Google Scholar
38	Katz M, Amit I and Yarden Y: Regulation of MAPKs by growth factors and receptor tyrosine kinases. Biochim Biophys Acta. 1773:1161–1176. 2007. View Article : Google Scholar : PubMed/NCBI
39	Tobiume K, Matsuzawa A, Takahashi T, Nishitoh H, Morita K, Takeda K, Minowa O, Miyazono K, Noda T and Ichijo H: ASK1 is required for sustained activations of JNK/p38 MAP kinases and apoptosis. EMBO Rep. 2:222–228. 2001. View Article : Google Scholar : PubMed/NCBI
40	Takeda K, Noguchi T, Naguro I and Ichijo H: Apoptosis signal-regulating kinase 1 in stress and immune response. Annu Rev Pharmacol Toxicol. 48:199–225. 2008. View Article : Google Scholar : PubMed/NCBI
41	Wu CC and Bratton SB: Regulation of the intrinsic apoptosis pathway by reactive oxygen species. Antioxid Redox Signal. 19:546–558. 2013. View Article : Google Scholar : PubMed/NCBI
42	Dhanasekaran DN and Reddy EP: JNK signaling in apoptosis. Oncogene. 27:6245–6251. 2008. View Article : Google Scholar : PubMed/NCBI
43	Chang L and Karin M: Mammalian MAP kinase signalling cascades. Nature. 410:37–40. 2001. View Article : Google Scholar : PubMed/NCBI
44	Suzuki S, Okada M, Shibuya K, Seino M, Sato A, Takeda H, Seino S, Yoshioka T and Kitanaka C: JNK suppression of chemotherapeutic agents-induced ROS confers chemoresistance on pancreatic cancer stem cells. Oncotarget. 6:458–470. 2015. View Article : Google Scholar : PubMed/NCBI
45	Sun ZL, Dong JL and Wu J: Juglanin induces apoptosis and autophagy in human breast cancer progression via ROS/JNK promotion. Biomed Pharmacother. 85:303–312. 2017. View Article : Google Scholar : PubMed/NCBI
46	Weston CR and Davis RJ: The JNK signal transduction pathway. Curr Opin Genet Dev. 12:14–21. 2002. View Article : Google Scholar : PubMed/NCBI